1 |
Bian D, Nichols ML, Ossipov MH, Lai J, Porreca F. Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. Neuroreport 1995; 6: 1981-4.
DOI
ScienceOn
|
2 |
Zhao C, Tall JM, Meyer RA, Raja SN. Antiallodynic effects of systemic and intrathecal morphine in the spared nerve injury model of neuropathic pain in rats. Anesthesiology 2004; 100: 905-11.
DOI
ScienceOn
|
3 |
George A, Marziniak M, Schä8fers M, Toyka KV, Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 2000; 88: 267-75.
DOI
ScienceOn
|
4 |
Rajkumar SV, Fonseca R, Witzig TE. Complete resolution of reflex sympathetic dystrophy with thalidomide treatment. Arch Intern Med 2001; 161: 2502-3.
DOI
ScienceOn
|
5 |
Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50: 355-63.
DOI
ScienceOn
|
6 |
Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
DOI
ScienceOn
|
7 |
Vale ML, Cunha FQ, Brito GA, Benevides VM, Ferreira SH, Poole S, et al. Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation. Eur J Pharmacol 2006; 536: 309-17.
DOI
ScienceOn
|
8 |
White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA 2007; 104: 20151-8.
DOI
ScienceOn
|
9 |
Rocha AC, Fernandes ES, Quintão NL, Campos MM, Calixto JB. Relevance of tumour necrosis factor-alpha for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw. Br J Pharmacol 2006; 148: 688-95.
DOI
ScienceOn
|
10 |
Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci 2001; 24: 450-5.
DOI
ScienceOn
|
11 |
Bennett GJ. A neuroimmune interaction in painful peripheral neuropathy. Clin J Pain 2000; 16(3 Suppl): S139-43.
DOI
|
12 |
Laffitte E, Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf 2004; 3: 47-56.
DOI
ScienceOn
|
13 |
Wallace JM. Update on pharmacotherapy guidelines for treatment of neuropathic pain. Curr Pain Headache Rep 2007; 11: 208-14.
DOI
ScienceOn
|
14 |
Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005; 10: 107-14.
DOI
ScienceOn
|
15 |
Backonja MM. Defining neuropathic pain. Anesth Analg 2003; 97: 785-90.
|
16 |
Barkin RL, Barkin SJ, Barkin DS. Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med 2005; 21: 465-90.
DOI
ScienceOn
|
17 |
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80.
DOI
ScienceOn
|
18 |
Lee YW, Chaplan SR, Yaksh TL. Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. Neurosci Lett 1995; 199: 111-4.
DOI
ScienceOn
|
19 |
Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F. Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci Lett 1995; 199: 83-6.
DOI
ScienceOn
|
20 |
Yu W, Hao JX, Xu XJ, Wiesenfeld-Hallin Z. Comparison of the anti-allodynic and antinociceptive effects of systemic; intrathecal and intracerebroventricular morphine in a rat model of central neuropathic pain. Eur J Pain 1997; 1: 17-29.
DOI
ScienceOn
|
21 |
Turk BE, Jiang H, Liu JO. Binding of thalidomide to alpha1- acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 1996; 93: 7552-6.
DOI
ScienceOn
|
22 |
Zimmermann M. Ethical guidelines for investigations on experimental pain in conscious animals. Pain 1983; 16: 109-10.
DOI
ScienceOn
|
23 |
Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-34.
DOI
ScienceOn
|
24 |
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55-63.
DOI
ScienceOn
|
25 |
DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001; 90: 1-6.
DOI
ScienceOn
|
26 |
Myers RR, Campana WM, Shubayev VI. The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today 2006; 11: 8-20.
DOI
ScienceOn
|
27 |
Arné.r S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33: 11-23.
DOI
ScienceOn
|
28 |
Dellemijn P. Are opioids effective in relieving neuropathic pain? Pain 1999; 80: 453-62.
DOI
ScienceOn
|
29 |
Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59: 1015-21.
DOI
ScienceOn
|
30 |
Xu JT, Xin WJ, Zang Y, Wu CY, Liu XG. The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain 2006; 123: 306-21.
DOI
ScienceOn
|
31 |
Ching DW, McClintock A, Beswick F. Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I: case report. J Clin Rheumatol 2003; 9: 96-8.
DOI
ScienceOn
|
32 |
Laffitte E. The revival of thalidomide: an old drug with new indications. Rev Prat 2006; 56: 1977-83.
|
33 |
Ribeiro RA, Vale ML, Ferreira SH, Cunha FQ. Analgesic effect of thalidomide on inflammatory pain. Eur J Pharmacol 2000; 391: 97-103.
DOI
ScienceOn
|